APPROACHING DEADLINE: Hagens Berman Reminds Endo International plc (NASDAQ: ENDP) Investors of July 25, 2016 Lead Plaintiff Deadline

SAN FRANCISCO, July 21, 2016 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds Endo International plc ENDP investors of the July 25, 2016 Lead Plaintiff deadline.

If you purchased or otherwise acquired securities of Endo International plc between March 2, 2015 and May 6, 2016 and suffered over $100,000 in losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit:

https://www.hbsslaw.com/cases/ENDP

or contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing ENDP@hbsslaw.com.

The litigation concerns the abrupt departure of a senior Endo officer, Endo's slashed revenue guidance given two months before, and law enforcement's investigation into Endo's contracts with Pharmacy Benefit Managers ("PBMs").

Endo announced on May 5 its President of U.S. Branded Pharmaceuticals segment (Brian Lortie) resigned.  The Company also reported a loss for the quarter ended March 31, 2016 and sharply reduced its targeted revenue guidance from that given just two months before.  On this news, the price of Endo's common stock fell 39.19% to $16.17 per share on May 6, 2016.

That morning, TheStreet's Jim Cramer said in CNBC'S "Squawk on the Street", "Something is not right here" and "I'm going to put [Endo] in a puzzle category."  CNBC's "Market Insider" reported "Endo shares are on pace for its worst daily performance since June 2002 when it fell more than 46 percent […] [s]hares have lost more than half their value so far this year."

The next day, Endo disclosed that in March 2016 it received a Civil Investigative Demand from the U.S. Attorney's Office for the Southern District of New York.  The U.S. Attorney requested documents and information regarding contracts with PBMs, which administer drug benefits for employers and health insurers. On this news, the price of Endo's common stock fell 5.7% to close at $15.27 on May 9, 2016.

"We're focused on a variety of Endo-related facts, in addition to the U.S. Attorney's investigation, Lortie's abrupt resignation, and the sharply reduced revenue guidance," said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding Endo International should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email ENDP@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm's Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.